OS Therapies (NYSE:OSTX) Now Covered by Analysts at Maxim Group

Maxim Group started coverage on shares of OS Therapies (NYSE:OSTX) in a research note issued to investors on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $8.00 price target on the stock.

A number of other research analysts have also recently issued reports on the stock. EF Hutton Acquisition Co. I raised shares of OS Therapies to a “strong-buy” rating in a report on Tuesday, September 3rd. Brookline Capital Management raised OS Therapies to a “strong-buy” rating in a report on Thursday, August 22nd.

OS Therapies Stock Up 3.0 %

Shares of OSTX opened at $2.06 on Tuesday. OS Therapies has a 52-week low of $1.58 and a 52-week high of $4.90. The company has a 50-day moving average of $2.75.

Institutional Trading of OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC acquired a new position in shares of OS Therapies Inc (NYSE:OSTX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.